- Home
- NRXP vs RFL Comparison
NRXP vs RFL Comparison
Compare NRXP & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXP | RFL |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.1M | 133.1M |
| IPO Year | 2017 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NRXP | RFL |
|---|---|---|
| Price | $2.68 | $1.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $38.50 | N/A |
| AVG Volume (30 Days) | ★ 537.4K | 149.3K |
| Earning Date | 11-16-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.70 | 28.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,225,000.00 | $917,000.00 |
| Revenue This Year | $357.94 | N/A |
| Revenue Next Year | $1,507.30 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $1.65 | $1.12 |
| 52 Week High | $5.06 | $3.96 |
Technical Indicators
Market Signals| Indicator | NRXP | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 32.34 | 33.21 |
| Support Level | $1.68 | $1.24 |
| Resistance Level | $3.62 | $1.58 |
| Average True Range (ATR) | 0.13 | 0.14 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 35.40 | 16.84 |
Price Performance
Historical ComparisonAbout NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.